Longpre Lara 4
4 · Mirum Pharmaceuticals, Inc. · Filed Feb 2, 2023
Insider Transaction Report
Form 4
Longpre Lara
Chief Development Officer
Transactions
- Award
Common Stock
2023-01-31+9,625→ 106,159 total - Award
Stock Option (right to buy)
2023-01-31+38,500→ 38,500 totalExercise: $23.48Exp: 2033-01-30→ Common Stock (38,500 underlying)
Footnotes (2)
- [F1]Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
- [F2]1/4th of the shares vest one year after January 31, 2023 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.